Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:COCP

Cocrystal Pharma 3/27/2025 Earnings Report

Cocrystal Pharma logo
$1.14 +0.03 (+2.25%)
As of 02:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Cocrystal Pharma EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.55
Beat/Miss
Beat by +$0.23
One Year Ago EPS
N/A

Cocrystal Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cocrystal Pharma Announcement Details

Quarter
Date
3/27/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Cocrystal Pharma's next earnings date is estimated for Thursday, May 21, 2026, based on past reporting schedules.

Conference Call Resources

Cocrystal Pharma Earnings Headlines

Cocrystal Pharma Inc
May 17, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/COCP
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
May 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/15/3295782/0/en/cocrystal-pharma-provides-business-update-and-reports-first-quarter-2026-financial-results.html
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it coming — but those who did walked away wealthy.Trump holds that same legal authority today. Advisors close to the administration believe he may use it.If he does, the transfer moves fast. The window to position yourself on the right side is already closing.tc pixel
May 21 at 1:00 AM  |  American Alternative (Ad)
Cocrystal Pharma (COCP) to Release Quarterly Earnings on Thursday
May 14, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30776584
Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection
April 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3285434/0/en/cocrystal-pharma-presentation-at-icar-2026-highlights-mechanism-of-action-and-clinical-advancement-of-cdi-988-for-the-prevention-and-treatment-of-norovirus-infection.html
Cocrystal Pharma (COCP) price target increased by 33.33% to 8.16
April 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/cocrystal-pharma-cocp-price-target-increased-by-33-33-to-8-16/ar-AA20VRKV
See More Cocrystal Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cocrystal Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cocrystal Pharma and other key companies, straight to your email.

About Cocrystal Pharma

Cocrystal Pharma (NASDAQ:COCP) (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections. Lead projects target influenza A and B polymerases as well as key enzymes in coronaviruses such as SARS-CoV-2. Additional research efforts are directed at antiviral targets in hepatitis B virus, norovirus and other emerging viral threats, reflecting Cocrystal’s commitment to addressing a broad spectrum of infectious diseases.

Founded in 2006 and headquartered in Bothell, Washington, Cocrystal Pharma leverages collaborations with academic institutions and contract research organizations to expand its drug discovery capabilities. The company maintains research laboratories in the Seattle area and operates a business development office in New York City to engage with strategic partners and investors globally.

Under the leadership of founder and Chief Executive Officer Kenneth T. Hitchcock, Ph.D., Cocrystal Pharma seeks to address unmet medical needs in antiviral therapy. By combining deep structural biology expertise with a scalable discovery engine, the company aims to advance novel antivirals poised to combat both seasonal outbreaks and future pandemic threats.

View Cocrystal Pharma Profile
Earnings Tools